The Pharma Data

MARCH 28, 2022

Dupixent peak sales ambition raised to more than €13 billion Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade 13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024.

Medicine 52

Medicine Sales Clinical Development Development 52

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

NOVEMBER 28, 2022

Tralokinumab is a high-affinity human monoclonal antibody that specifically targets and neutralises interleukin (IL)-13 cytokine, which plays an important role in the immune and inflammatory processes underlying AD signs and symptoms.

Dermatology 52

Dermatology Trials Medicine Antibody 52

pharmaphorum

OCTOBER 22, 2021

Dupixent is already approved to treat atopic dermatitis and other indications including severe asthma and chronic rhinosinusitis with nasal polyposis, and has become a powerhouse for revenues at Sanofi and Regeneron, with analysts predicting peak sales could go as high a $12.5

Trials 105

Trials Sales Antibody Drugs 105

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs 69

Drugs Immune Response Allergies Sales 69

pharmaphorum

AUGUST 24, 2021

Analysts at Jefferies think that Bimzelx’ profile could drive it to sales of more than $2 billion a year, assuming it also gets approved in follow-up indications psoriatic arthritis and ankylosing spondylitis. For now though, the drugmaker is going it alone.

Sales 52

Sales Marketing Drugs Antibody 52

pharmaphorum

APRIL 26, 2021

The drug is a nanobody, a molecule around one-tenth the size of a regular antibody derived from camelid species such as the llama. Proponents say they can offer greater stability, smaller size, higher potency, and lower production or synthesis costs compared to conventional monoclonal antibodies. billion in sales last year.

Antibody 52

Antibody Drugs Marketing Licensing 52

pharmaphorum

AUGUST 16, 2021

billion to take control of lebrikizumab’s developer Dermira last year after the antibody showed promising results in phase 2b trials, and has been waiting for the results of the phase 3 trials to see if that was a good move. Lilly shelled out $1.1

Antibody 52

Antibody Trials Marketing Drugs 52

pharmaphorum

MAY 25, 2022

But while the company is adamant sales will pick up quickly, analysts have predicted a more challenging start for the new product. Dermavant has said it is planning a swift rollout for Vtama, with the commercial team in place for a launch early next month.

Drugs 52

Drugs FDA Approval Licensing Licensing 52

pharmaphorum

AUGUST 2, 2021

Analysts at Jefferies have previously said that the antibody could achieve peak sales of more than $2 billion a year if its approved for psoriasis and follow-up indications psoriatic arthritis and ankylosing spondylitis, even though the categories are getting increasingly crowded.

Marketing 52

Marketing Medicine Production Sales 52

pharmaphorum

JANUARY 6, 2023

As Dr Shao-Lee Lin, founder and CEO of ACELYRIN, commented: “The acquisition of ValenzaBio adds additional programmes to our portfolio, such as lonigutamab.”.

Trials 59

Trials Marketing Protein Antibody 59

The Pharma Data

AUGUST 1, 2021

Saphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus . Under the agreement AstraZeneca will pay BMS a low to mid-teens royalty for sales dependent on geography. 17,18 At least five million people worldwide have a form of lupus.

Trials 52

Trials Clinical Development Antibody Dermatology 52

The Pharma Data

NOVEMBER 8, 2020

9, 2020 /PRNewswire/ — Solid 9M business performance despite COVID-19 and generic Aczone challenges: Net Sales €613.8 Ilumetri ® sales grew +125% year-on-year and Seysara ® showed Net Sales performance improvement quarter-on-quarter following clinically relevant FDA label improvement. BARCELONA, Spain , Nov.

Dermatology 52

Dermatology Sales Marketing Production 52

The Pharma Data

DECEMBER 17, 2020

Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. Martin Carter Professor in Clinical Investigation and Head of the Laboratory of Investigative Dermatology at The Rockefeller University and Weinblatt is the co-director of Clinical Rheumatology at the Brigham and Women’s Hospital.

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

AUGUST 19, 2020

The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. In autoantibody-driven diseases, the body’s antibodies attack or damage its own proteins, cells and tissues, often with devastating consequences.

Production 52

Production Dermatology Development Containment 52

pharmaphorum

MAY 4, 2021

German Merck also received an undisclosed milestone payment and will be eligible for development and commercial milestone payments as well as “industry standard” royalties on net sales. Sonelokimab is a single-domain antibody – a fragment of an antibody that can bind specifically to an antigen with high affinity.

Licensing 52

Licensing Licensing Dermatology Antibody 52

The Pharma Data

AUGUST 19, 2020

The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. In autoantibody-driven diseases, the body’s antibodies attack or damage its own proteins, cells and tissues, often with devastating consequences.

Production 40

Production Dermatology Development Containment 40

The Pharma Data

OCTOBER 9, 2021

Tezepelumab Tezepelumab is being developed by AstraZeneca in collaboration with Amgen as a potential first-in-class human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades.

Drugs 52

Drugs Sales Medicine Dermatology 52

The Pharma Data

JULY 8, 2021

Tezepelumab Tezepelumab is a potential first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 52

Trials Medicine Sales Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

On a non-risk adjusted basis, these opportunities collectively represent more than $15 billion (excluding 20vPnC) in potential incremental revenue for Pfizer from 2020 to 2025, as well as aggregate peak annual sales potential of $35 billion to $40 billion (including 20vPnC). for RSV A and 18.0 Inflammation and Immunology.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52